New York is currently home to 4470 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
Recruiting
This study is a prospective, multi-center, randomized, double blinded, placebo-controlled study of OCR treatment-discontinuation in patients with early RMS. All eligible participants will be initiated on OCR using the standard approved administration schedule of two 300 mg infusions separated by 14 days (i.e., Days 0 and 14) for a total of 600 mg, followed by 600 mg infusions at Month 6,12, 18, and 24. At Month 24, participants will be randomized (2:1) to one of two Arms with randomized treatmen... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
12/03/2024
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Multiple Sclerosis
Impact of Biosynthetic Mesh on Paraesophageal Hernia Repair
Recruiting
The aim of this study is to find out if using a certain kind of mesh can reduce the chances of hiatal hernias coming back after anti-reflux surgery. Participants undergoing antireflux surgery will be assigned to one of two groups, a group that has surgery with mesh, or a group that has surgery without mesh.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/02/2024
Locations: NYU Langone Health, New York, New York
Conditions: Hiatal Hernia
Community-Based Physical Activity Intervention for Underserved Cancer Survivors
Recruiting
This clinical trial evaluates a community-based physical activity program for underserved cancer survivors. Cancer and its treatment significantly influence physical, psychosocial, and cognitive functioning. Historically, community sites (local and national) have not been staffed to offer support services such as physical, and occupational therapies (everyday life activities to promote health and well-being) or nutrition counselling, and do not offer a whole-person model of care. In this study,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/02/2024
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC
Recruiting
The purpose of this study is to identify the recommended dose of vudalimab to be used in combination with chemotherapy (Part 1) and to evaluate the efficacy and safety of vudalimab plus standard of care chemotherapy relative to pembrolizumab plus chemotherapy (Part 2) as first-line treatment in patients with nonsquamous non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/02/2024
Locations: Cancer Institute at Phelps, Sleepy Hollow, New York
Conditions: Nonsquamous Non-small Cell Lung Cancer
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
Recruiting
This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV). Ritlecitinib is studied in patients with non-segmental vitiligo. Vitiligo is a chronic acquired depigmentation disorder characterized by well-defined pale white patches of skin. Non-segmental vitiligo is an autoimmune disorder and is the focus of this study. The study will show: * if the repigmentation (the recovery of pigmentation) achieved in study B7981040 (also called the "p... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
12/02/2024
Locations: SUNY Downstate Health Sciences University, Brooklyn, New York
Conditions: Vitiligo
Electrical Stimulation for the Treatment of Glaucoma
Recruiting
The overall aim of this study is to see whether long-term electrical stimulation with a home-stimulation device works well and is safe for the treatment of open-angle glaucoma. Open-Angle Glaucoma is a disease where the nerves in the back of your eye die off faster than expected regardless of your eye pressure.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/02/2024
Locations: NYU- Langone, New York, New York
Conditions: Glaucoma, Glaucoma, Open-Angle
Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial
Recruiting
The primary objective is to establish the efficacy of intra-arterial (IA) mechanical thrombectomy (MT) with extracranial proximal carotid artery acute stenting versus non-stenting approaches in patients with acute ischemic stroke (AIS) from intracranial vessel occlusion (IVO) in the anterior circulation and have a proximal carotid occlusive disease (occlusion or severe stenosis).
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
12/02/2024
Locations: Albany Medical College, Albany, New York
Conditions: Acute Ischemic Stroke
Vincristine Pharmacokinetics in Infants
Recruiting
This pilot trial compares drug exposure levels using a new method for dosing vincristine in infants and young children compared to the standard dosing method based on body surface area (BSA) in older children. Vincristine is an anticancer drug used to a variety of childhood cancers. The doses anticancer drugs in children must be adjusted based on the size of the child because children vary significantly in size (height, weight, and BSA) and ability to metabolize drugs from infancy to adolescence... Read More
Gender:
ALL
Ages:
12 years and below
Trial Updated:
12/02/2024
Locations: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York
Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Cardiopulmonary Outcomes in Osteogenesis Imperfecta: BBD7708
Recruiting
Osteogenesis imperfecta (OI) is a group of congenital and heritable bone disorders that currently affects at least 50,000 people in the United States. OI varies in severity from perinatally lethal to mild forms. The majority of cases is caused by a dominant mutation in type I collagen genes (COL1α1 and COL1α2), altering the quantity or quality of type I collagen. Although OI is typically characterized as a disease of the bone, it is perhaps more accurately described as a connective tissue disor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/02/2024
Locations: Hospital for Special Surgery, New York, New York
Conditions: Osteogenesis Imperfecta
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
Recruiting
The rationale for the study is to obtain safety and efficacy data as well as to establish dose parameters for the SpectraCure P18 System with IDOSE®, with verteporfin for injection (VFI) as photosensitizer for the treatment of recurrent prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
12/02/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Recurrent Prostate Cancer
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
Recruiting
The purpose of study is to evaluate the efficacy of the electrical muscle stimulation (EMS) device in patients with patellofemoral pain known as anterior knee pain. Usual treatment for it is physical therapy (PT). We want to evaluate and see if adding the electrical muscle stimulation will fasten the recovery and improved outcome in patellofemoral pain syndrome. Half of participants will receive EMS and PT while other half will receive PT only.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
11/28/2024
Locations: New York Bone and Joint Specialists, New York, New York
Conditions: Patellofemoral Pain Syndrome
STXBP1 and SYNGAP1 Related Disorders Natural History Study
Recruiting
The purpose of this study is to find out more about STXBP1 and SYNGAP1 related disorders. The information gathered by this study will be used to prepare for clinical treatment trials. The primary objective of the study is to better define and outline the clinical spectrum of STXBP1 and SYNGAP1 through detailed developmental, seizure, and quality of life assessments as an extension of routine clinical care.
Gender:
ALL
Ages:
All
Trial Updated:
11/27/2024
Locations: Weill Cornell Medicine, New York, New York
Conditions: Genetic Disease, STXBP1 Encephalopathy With Epilepsy, SYNGAP1-Related Intellectual Disability